Abstract
Many oncolytic viruses are currently being tested as potential cancer therapeutic agents. To be effective, these viruses must replicate and propagate efficiently through the tumor mass. However, it is possible that the hypoxia that characterizes many tumors may be an obstacle to viral therapy because of its inhibition of viral replication and propagation. We, therefore, decided to test how oncolytic reovirus and its target cells respond to hypoxia. We found that reovirus infection suppresses hypoxia inducible factor (HIF)-1α protein levels (but not transcript abundance) in colon cancer HCT116 cells under CoCl2 or hypoxia. Reovirus infection was able to reduce HIF-1α levels in both von Hippel Lindau (VHL)−/− renal carcinoma A498 and p53−/− HCT116 cells, indicating that the decrease of HIF-1α mediated by reovirus requires neither VHL nor p53 proteins. However, treatment with the inhibitor MG132 restored HIF-1α levels, suggesting that reovirus-induced HIF-1α decrease needs proteosomal activity. A498 VHL−/− cells with constitutive expression of HIF-1α were relatively resistant to reovirus-induced apoptosis when compared with A498 VHL+/+ cells. However, we found that the use of YC-1 to target HIF-1α promoted reovirus-induced apoptosis in A498 VHL−/− cells. Accordingly, we propose that reovirus may be used together with YC-1 as a potential therapeutic agent against chemoresistant or radioresistant tumors that are hypoxic and show increased levels of HIF-1α.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hockel M, Vaupel P . Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266–276.
Brown JM, Wilson WR . Exploiting tumour hypoxia in cancer treatment. Nat Rev 2004; 4: 437–447.
Bardos JI, Ashcroft M . Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004; 26: 262–269.
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (New York, NY) 2001; 292: 468–472.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–275.
Tanimoto K, Makino Y, Pereira T, Poellinger L . Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19: 4298–4309.
Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW . Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad SciUSAm 2004; 101: 11099–11104.
Kim M, Chung YH, Johnston RN . Reovirus and tumor oncolysis. J Microbiol (Seoul, Korea) 2007; 45: 187–192.
Rosen L, Evans HE, Spickard A . Reovirus infections in human volunteers. Am J Hyg 1963; 77: 29–37.
Nibert ML, Schiff LA, Fields BN . Mammalian reoviruses contain a myristoylated structural protein. J Virol 1991; 65: 1960–1967.
Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway. Science (New York, NY) 1998; 282: 1332–1334.
Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348–353.
Park EH, Koh SS, Srisuttee R, Cho IR, Min HJ, Jhun BH et al. Expression of HBX, an oncoprotein of hepatitis B virus, blocks reoviral oncolysis of hepatocellular carcinoma cells. Cancer Gene Ther 2009; 16: 453–461.
Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004; 10: 8561–8576.
Ring CJ . Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83 (Part 3): 491–502.
Russel FG, Masereeuw R, van Aubel RA . Molecular aspects of renal anionic drug transport. Ann Rev Physiol 2002; 64: 563–594.
Norman KL, Lee PW . Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005; 10: 847–855.
Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M, Tsukuda M . Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris, Nasus, Larynx 2004; 31: 407–412.
Janssen HL, Higuchi H, Abdulkarim A, Gores GJ . Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 2003; 39: 414–420.
Clarke P, Meintzer SM, Spalding AC, Johnson GL, Tyler KL . Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 2001; 20: 6910–6919.
Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC . YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997; 320: 161–166.
Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001; 61: 947–954.
Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95: 516–525.
Giaccia A, Siim BG, Johnson RS . HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803–811.
Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y et al. Reovirus therapy of lymphoid malignancies. Blood 2002; 100: 4146–4153.
Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J . Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26: 2019–2028.
Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772–5781.
Levine AJ . p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331.
Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD . p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22: 395–405.
Kim HY, Kim YH, Nam BH, Kong HJ, Kim HH, Kim YJ et al. HIF-1alpha expression in response to lipopolysaccaride mediates induction of hepatic inflammatory cytokine TNFalpha. Exp Cell Res 2007; 313: 1866–1876.
Yoo YG, Oh SH, Park ES, Cho H, Lee N, Park H et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003; 278: 39076–39084.
Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS . Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 2004; 24: 5223–5234.
Cheng J, Kang X, Zhang S, Yeh ET . SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007; 131: 584–595.
Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL . RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007; 25: 207–217.
Hwang II, Watson IR, Der SD, Ohh M . Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol 2006; 80: 10712–10723.
Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F et al. Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res 2006; 66: 1684–1936.
Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96: 946–956.
Escuin D, Kline ER, Giannakakou P . Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65: 9021–9028.
Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G . The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2003; 2: 235–243.
Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 2007; 26: 3941–3951.
Acknowledgements
This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean government (MEST) (2009-0071348) and by grant no. R31-2008-000-20004-0 from WCU project of the MEST and the KOSEF (YHC). This work was also supported by the Research Program for New Drug Target Discovery (M10748000195-08N4800-19510) grant from the Ministry of Education, Science and Technology to SSK.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Cho, IR., Koh, S., Min, HJ. et al. Down-regulation of HIF-1α by oncolytic reovirus infection independently of VHL and p53. Cancer Gene Ther 17, 365–372 (2010). https://doi.org/10.1038/cgt.2009.84
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2009.84